BEGHETTO, Barbara
 Distribuzione geografica
Continente #
NA - Nord America 6.461
EU - Europa 4.532
AS - Asia 3.558
SA - Sud America 421
AF - Africa 67
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 4
Totale 15.055
Nazione #
US - Stati Uniti d'America 6.318
IT - Italia 1.812
GB - Regno Unito 1.057
CN - Cina 1.032
SG - Singapore 1.005
SE - Svezia 442
HK - Hong Kong 371
VN - Vietnam 334
BR - Brasile 328
DE - Germania 298
TR - Turchia 228
FI - Finlandia 177
UA - Ucraina 176
BD - Bangladesh 165
FR - Francia 146
RU - Federazione Russa 114
KR - Corea 107
IN - India 105
CA - Canada 73
NL - Olanda 62
BG - Bulgaria 61
MX - Messico 39
AR - Argentina 34
ID - Indonesia 33
PL - Polonia 25
IQ - Iraq 24
LT - Lituania 21
ES - Italia 19
IE - Irlanda 19
IR - Iran 18
PK - Pakistan 18
BE - Belgio 17
CO - Colombia 16
SA - Arabia Saudita 15
ZA - Sudafrica 15
IL - Israele 14
JP - Giappone 13
EC - Ecuador 12
SI - Slovenia 12
AT - Austria 11
CH - Svizzera 11
EU - Europa 11
CL - Cile 9
MA - Marocco 9
AE - Emirati Arabi Uniti 8
DZ - Algeria 8
PH - Filippine 8
TH - Thailandia 8
CR - Costa Rica 7
EG - Egitto 7
MY - Malesia 7
NG - Nigeria 7
UZ - Uzbekistan 7
CZ - Repubblica Ceca 6
GR - Grecia 6
JO - Giordania 6
PE - Perù 6
RO - Romania 6
VE - Venezuela 6
BY - Bielorussia 5
DK - Danimarca 5
JM - Giamaica 5
KE - Kenya 5
SK - Slovacchia (Repubblica Slovacca) 5
TN - Tunisia 5
AU - Australia 4
DO - Repubblica Dominicana 4
KZ - Kazakistan 4
PA - Panama 4
PY - Paraguay 4
RS - Serbia 4
TW - Taiwan 4
UY - Uruguay 4
GE - Georgia 3
GT - Guatemala 3
NP - Nepal 3
SN - Senegal 3
AL - Albania 2
AZ - Azerbaigian 2
BH - Bahrain 2
BO - Bolivia 2
CU - Cuba 2
CY - Cipro 2
EE - Estonia 2
ET - Etiopia 2
HN - Honduras 2
KG - Kirghizistan 2
LB - Libano 2
LV - Lettonia 2
MD - Moldavia 2
MG - Madagascar 2
NI - Nicaragua 2
PT - Portogallo 2
QA - Qatar 2
TJ - Tagikistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
CI - Costa d'Avorio 1
GA - Gabon 1
HR - Croazia 1
Totale 15.044
Città #
Southend 781
Santa Clara 771
Singapore 677
Ashburn 578
Woodbridge 461
Fairfield 389
Chandler 385
Hong Kong 364
Jacksonville 323
Hefei 285
Ann Arbor 251
Houston 241
Nyköping 235
Beijing 234
San Jose 232
Dearborn 223
Wilmington 182
Rome 170
Milan 165
London 151
Cambridge 143
Seattle 137
Dallas 131
Izmir 123
Los Angeles 113
Helsinki 110
Seoul 105
Ho Chi Minh City 95
The Dalles 84
New York 81
Buffalo 73
Naples 73
Hanoi 72
Princeton 67
Council Bluffs 59
Sofia 58
Chicago 57
Eugene 57
Frankfurt am Main 57
Modena 56
San Diego 55
Lauterbourg 48
Shanghai 44
Munich 38
Bari 36
Moscow 34
São Paulo 33
Bologna 32
Florence 31
Palermo 31
Des Moines 29
Da Nang 26
Orem 26
Chennai 23
Turin 21
Brescia 20
Catania 19
Guangzhou 19
Philadelphia 19
Mexico City 18
Dublin 17
Mumbai 17
Toronto 17
Brussels 16
Elk Grove Village 16
Warsaw 16
Columbus 15
Falkenstein 15
Jakarta 15
Montreal 15
Atlanta 14
Boardman 14
Memphis 14
Nanjing 14
Salt Lake City 14
Augusta 13
Bremen 13
Haiphong 13
Phoenix 13
San Mateo 13
Turku 13
Baghdad 12
Johannesburg 12
Stockholm 12
Brooklyn 11
Genoa 11
Ottawa 11
Redwood City 11
Denver 10
Ferrara 10
Kent 10
Kunming 10
Mashhad 10
Norwalk 10
Parma 10
Shenzhen 10
Tokyo 10
Amsterdam 9
Changsha 9
Perugia 9
Totale 9.955
Nome #
Un raro caso di prostatite da Candida albicans, Candida krusei ed Enterococcus fecium 1.761
Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy 361
Aging with HIV vs. HIV Seroconversion at Older Age: A Diverse Population with Distinct Comorbidity Profiles 356
18Fluoride-based molecular imaging of coronary atherosclerosis in HIV infected patients 343
Molecular Imaging of Vascular Calcification with 18 F-Sodium-Fluoride in Patients Infected with Human Immunodeficiency Virus 308
Long-term psychometric outcomes of facial lipoatrophy therapy: Forty-eight-week observational, nonrandomized study 307
The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection 305
Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study 305
Alendronate reduces bone turnover in HIV-associated Osteopenia and Osteoporosis 292
Autologous fat transfer for treating facial wasting in HIV body fat redistribution syndrome. 286
Detectable HIV viral load is associated with metabolic syndrome 283
Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection 278
Associatioin of epicardial adipose tissue with incident coronary heart disease and death in HIV infected patients. 278
Prediction of hard cardiovascular events in HIV patients 276
A randomized, controlled trial to evaluate change in cardiometabolic and endothelial function in HIV-infected patients with optimal viral suppression on Darunavir/ritonavir monotherapy vs. triple-therapy. 273
Autologous fat transfer for treating facial wasting in HIV-related lipodystrophy: experience of 53 treated patients 271
Severity of lipodystrophy is associated with decreased health-related quality of life 269
Effectiveness and durability of polyacrylamide hydrogel injections for treating HIV-related facial lipoatrophy 267
Psychometric evaluation of patients undergoing surgical treatment of HIV-related facial lipoatrophy 255
Prevalence of and risk factors for pubic lipoma development in HIV-infected persons 255
Age-related comorbidities in people living with HIV 252
Prospective, partially randomized, 24-week study to compare the efficacy and durability of different surgical techniques and interventions for the treatment of HIV-related facial lipoatrophy 246
Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV 240
Randomized Trial to Evaluate Cardiometabolic and Endothelial Function in Patients with Plasma HIV-1 RNA Suppression Switching to Darunavir/Ritonavir with or without Nucleoside Analogues 231
Morphologic alterations in HIV infected people with lipodystropy are associated with good adherence to HAART. 230
ISS-NIA ITALIAN COHORT: NEW ANTI-HIV INHIBITORS IN PATIENTS EXPERIENCED TO IP, NRTI, NNRTI. 226
Does lipodistrophy affect quality of life? 225
Autologous fat transfer for treating facial waisting in HIV body fat redistribution Syndrome 222
Body Image perception in HIV infected women with body fat redistribution. 219
Candidemia nosocomiale: quattro anni di esperienza in un'ospedale universitario italiano 219
Effectiveness and long-term durability of autologous fat transplant for HIV-related face lipoatrophy. 218
Psychometric evaluation in patients undergoing fillers injections for the treatment of HIV-related facial lipoatrophy: polylactic acid versus polyacrylamide 217
Efficacy and safety of medical and surgical interventions for treating HIV-related lipodystrophy in women 215
Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: The Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) study 208
Long lasting psycho-social benefits of polyacrylamide injections for the treatment of facial lipoatrophy 207
Long-term follow-up of graft hypertrophy after autologous fat transfer for HIV-related face lipoatrophy (hamster syndrome 1 year later) 205
How do frailty mediate pathway leading to disability 201
Quality of life and body image in the assessment of psychological impact of lipodystrophy: validation of the italian version of assessment of body change and distress questionnaire 200
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: A cross-sectional study 198
The role of virological and immunological parameters on the diagnosis of metabolic syndrome in HIV-associated lipodystrophy 196
È possibile un counselling HIV su internet? 196
Virologic failure and metabolic syndrome in patients with HIV infection 193
Validity of body image perception in women with HIV. 188
Virologic failure and metabolic syndrome in patients with HIV infection 186
Limited occurrence of new grade 3-4 toxicity events with salvage regimens based on raltegravir and /or maraviroc: 96 weeks data from the ISS NIA cohort study. 184
Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC vs. B/F/TAF: the DEBATE trial 179
Mechanical and ultrasound-assisted liposuction for treating subcutaneous fat accumulations in HIV-related lipodystrophy: experience of 33 treated patients 179
Prevalence and risk factors of pubic lipomas in HIV-infected patients 178
Prospective, 48 weeks follow up, multidisciplinary interventionalstudy to assess improvement of adherence in people with lipodistrophy. 173
Relapse of HIV-related buffalo hump after liposuction 172
Limited occurence of new grade 3-4 toxicity events with salvage regimens based on raltegravir and /or maraviroc: 96 weeks data from the ISS NIA cohort study 166
HIV counselling looks for new target and methods web versus face to face counselling 163
Qual è il rapporto tra qualità di vita e lipodistrofia 162
Lipodystrophy and quality of life: a prospective study 158
Ruolo della chirurgia plastica nel trattamento della sindrome da ridistribuzione del tessuto adiposo 157
Nuovi obiettivi e strumenti di lavoro nel counselling HIV: studio prospettico osservazionale del counselling informatico versus il counselling vis a vis 148
Metabolic and anthropometric alterations in a population of HIV infected patients with a high prevalence of lipodystrophy: associations with HCV coinfection 145
Gender differences in depression evolution in a cohort of patients attendine a metabolic clinic for lipodystrophy management 136
Tenofovir treatment in HIV-related lipodystrophy syndrome. Retrospective observational forty-eight weeks follow-up study 134
Lipodistrophy is related to adherence to antiretroviral therapy (ARV) 134
HIV counselling and prevention on the WEB 131
Totale 15.166
Categoria #
all - tutte 50.121
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.121


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202165 0 0 0 0 0 0 0 0 0 0 0 65
2021/2022914 21 136 62 104 23 43 34 76 95 66 142 112
2022/20231.398 140 121 111 109 121 178 38 152 180 45 107 96
2023/20241.039 60 71 81 130 165 79 91 98 34 49 60 121
2024/20252.816 113 77 60 224 589 403 214 130 336 97 259 314
2025/20264.660 309 222 473 544 541 346 508 268 498 420 281 250
Totale 15.166